Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy

Journal of Inherited Metabolic Disease

Volumn 37, Issue 6, 2014, Pages 991-1001

  van Dussen, L ^a   Hendriks, E J ^a   Groener, J E M ^a   Boot, R G ^a   Hollak, C E M ^a   Aerts, J M F G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; HEMOGLOBIN; MIGLUSTAT; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DISEASE; CHILD; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GAUCHER DISEASE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PARKINSON DISEASE; PULMONARY HYPERTENSION; THROMBOCYTE COUNT; BLOOD; LIVER; MACROPHAGE; METABOLISM; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; SPLEEN; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HEXOSAMINIDASES; HUMANS; LIVER; MACROPHAGES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLEEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911998784     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9711-x     Document Type: Article

References (46)

1. Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin Haematol 10(4):691–709
2. Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG (2005) Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl 94(447):43–46
3. Aerts JM, Kallemeijn WW, Wegdam W et al (2011) Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 34(3):605–619
4. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278(42):40911–40916
5. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 87(5):1913–1916
6. Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324(21):1464–1470
7. Boot RG, Renkema GH, Verhoek M et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273(40):25680–25685
8. Boot RG, Verhoek M, de Fost M et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103(1):33–39
9. Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM (2010) Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta 411(1–2):31–36
10. Bussink AP, Speijer D, Aerts JM, Boot RG (2007) Evolution of mammalian chitinase(−like) members of family 18 glycosyl hydrolases. Genetics 177(2):959–970
11. Bussink AP, Verhoek M, Vreede J et al (2009) Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J 276(19):5678–5688
12. Czartoryska B, Tylki-Szymanska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33(2):147–149
13. de Fost M, Hollak CE, Groener JE et al (2006a) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108(3):830–835
14. de Fost M, vom Dahl S, Weverling GJ (2006b) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36(1):53–58
15. de Fost M, Out TA, de Wilde FA et al (2008a) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87(6):439–449
16. de Fost M, van Noesel CJ, Aerts JM, Maas M, Poll RG, Hollak CE (2008b) Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93(7):1119–1120
17. Deegan PB, Moran MT, McFarlane I et al (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35(2):259–267
18. Deegan PB, Pavlova E, Tindall J et al (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90(1):52–60
19. Dekker N, van Dussen L, Hollak CE et al (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118(16):e118–e127
20. den Bakker MA, Grunberg K, Boonstra A, van Hal PT, Hollak CE (2012) Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease. Histopathology 61(2):324–326
21. Erjavec Z, Hollak CE, de Vries EG (1999) Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 10(2):243
22. Giraldo P, Irun P, Alfonso P et al (2011) Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis 46(1):115–118
23. Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M (2010) Enzyme replacement therapy “drug holiday”: Results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis 46:107–110
24. Grabowski GA, Petsko GA, Kolodny EH (2010) Gaucher disease. McGraw-Hill, New York
25. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3):1288–1292
26. Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27(6):1005–1012
27. Hollak CE, de Fost M, van Dussen L, vom Dahl S, Aerts JMFG (2009) Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose–response relationships. Expert Opin Pharmacother doi: 10.1517/14656560903270520
28. Kuter DJ, Mehta A, Hollak CE et al (2013) Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 51(2):116–124
29. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, den Heeten GJ (2002) Quantification of skeletal involvement in adults with type I Gaucher’s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179(4):961–965
30. Mistry PK, Sirrs S, Chan A et al (2002) Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77(1–2):91–98
31. Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89(9):691–694
32. Pavlova EV, Deegan PB, Tindall J et al (2011) Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis 46(1):27–33
33. Poll LW, Koch JA, Willers R et al (2002) Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 28(2):209–220
34. Roberts WC, Fredrickson DS (1967) Gaucher’s disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation 35(4):783–789
35. Roca M, Mota J, Alfonso P, Pocovi M, Giraldo P (2007) S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol 62(1):132–137
36. Rosenthal DI, Doppelt SH, Mankin HJ et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96(4 Pt 1):629–637
37. Schoonhoven A, Rudensky B, Elstein D et al (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381(2):136–139
38. Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72(1):219–224
39. Sirrs S, Casey R, Patterson MA, McNeil C, Paquin W, Amato D (2013) Variation in chitotriosidase values measured on simultaneous samples by two commercial laboratories. Am J Hematol 88(11):980
40. Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73(4):313–321
41. van Dussen L, Lips P, Everts VE et al (2011) Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab 96(7):2194–2205
42. van Dussen L, Cox TM, Hendriks EJ et al (2012) Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica 97(12):1850–1854
43. van Eijk M, van Roomen CP, Renkema GH et al (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17(11):1505–1512
44. Xu R, Mistry P, McKenna G et al (2005) Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis 25(2):226–229
45. Young E, Chatterton C, Vellodi A, Winchester B (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis 20(4):595–602
46. Zimran A, Altarescu G, Elstein D (2010) Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 46:111–114